TOC entry: Introduction of a substituent into the 19-position of the naturally occurring Hsp90 inhibitor geldanamycin by chemical synthesis not only ameliorates toxicity by blocking attack of thiol nucleophiles, but also causes a favourable conformational switch of the trans-amide group into the cis-form required for protein binding.
3 addition, the modulation of protein folding is also relevant to neurodegenerative diseases, and a number of conditions such as Alzheimer's and Parkinson's diseases are thought to be associated with protein misfolding and aggregation. [8] [9] [10] [11] [12] [13] [14] One compound that has played a very major role in the Hsp90 arena is the benzoquinone ansamycin (BQA) geldanamycin, although its use is limited due to hepatotoxicity observed in preclinical studies, 15 possibly as a result of reaction with biological nucleophiles at the reactive 19-position of the quinone ring. [16] [17] [18] Therefore we reasoned that blocking the reactive 19-position might suppress reaction with biological nucleophiles, ameliorate toxicity, and also result in a conformational change, arising from amide trans to cis isomerism. We now report the realisation of this hypothesis: introduction of a substituent at C-19 does indeed cause the desired conformational switch, whilst also blocking reaction with thiol nucleophiles, and, importantly, markedly reducing toxicity to normal endothelial and epithelial cells. Additionally, studies in both human breast cancer cells and dopaminergic neural cells established that the novel 19-substituted BQAs are effective inhibitors of Hsp90, suggesting that such rationally modified compounds have potential for application in the therapy of cancer and neurodegenerative diseases.
Geldanamycin 1, a naturally occurring BQA polyketide is a potent inhibitor of Hsp90 and its binding to the N-terminal domain has been studied by X-ray crystallography, 19, 20 and by NMR spectroscopy. 21 In preclinical studies, geldanamycin was found to exhibit significant hepatotoxicity, 15 and hence other less toxic, and more soluble, benzoquinone ansamycins such as 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) 2 and 17-(2-dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG, alvespimycin) 3 were developed. Whilst 17-AAG (tanespimycin) 2 showed some promise in Phase II trials, demonstrating activity in HER2/ERRB2 positive trastuzumab-refractory breast cancer, 22 development of the compound has been halted, further emphasizing the need for less toxic derivatives
In neuroscience, protein misfolding can be regulated by chaperones such as Hsp70, which paradoxically can be induced by inhibition of Hsp90. The chaperones Hsp90 and 70 exhibit very different specificity with respect to client protein interactions, providing a mechanism whereby inhibiting one chaperone (Hsp90) while inducing another (Hsp70) can be beneficial in specific diseases. Hence Hsp90 has now emerged as a target to prevent neurodegeneration, [8] [9] [10] [11] [12] [13] [14] and Hsp90
inhibitors have been employed as protective therapies in mouse models of Parkinson's disease. 23 The
BQAs, geldanamycin and 17-AAG, have been found to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced dopaminergic neurotoxicity in mice, 23 and other models of neurodegenerative disease. 9, [24] [25] [26] However, if such BQAs are to be considered as potential therapeutic agents for neurodegenerative disease, there is an urgent need to reduce their toxicity, whilst retaining or improving the potency.
The toxicity has been proposed to arise from the reaction of biological nucleophiles, particularly glutathione, at the unsubstituted 19-position of the quinone ansamycin. [16] [17] [18] We reasoned that the conjugation of glutathione (or other nucleophiles) might be suppressed by blocking the 19-position of the BQAs, and, as a result, the toxicity issues might be ameliorated. In addition, we also hypothesized that the introduction of a substituent at C-19 would result in conformational changes in the macrocyclic ring, arising from the 19-substituent causing amide trans to cis isomerism as a result of steric strain. We now report the first studies on the design and synthesis of a range of such 19- 
Results and Discussion

Compound design and rationale
The BQA macrocycles are known to adopt an extended trans-amide conformation in the solid state as evidenced by X-ray crystal structures of geldanamycin 1 itself, 27 and the 17-azetidinyl compound
4.
28 Early NMR spectroscopic studies on the solution conformation of BQA 4 also suggested a transamide conformation on the basis of the strong nuclear Overhauser effect (nOe) enhancement between the NH and the alkene H-3 ( Figure 1 ). 28 In contrast, protein crystallography studies using either yeast or human Hsp90 have shown that on binding, geldanamycin 1 and 17-DMAG 3 adopt a more closed "C-clamp" conformation with a cis-amide bond, 19, 20, 29 and therefore the isomerization 6 equilibrium ( Figure 1) In addition, couplings under milder conditions (those at lower temperature or with mild or no base) also proved to be problematic, with only formation of geldanamycin itself observed, presumably due to competing reductive catalytic processes. We hypothesized that these findings may be due to the transmetallation step in the catalytic cycle being slower than that for a competing pathway. Thus, we subjected our substrate to modified conditions that have been reported to address such problems, focusing on the Stille reaction since this is generally considered as the mildest of Pd-catalyzed crosscoupling processes.
The replacement of phosphine ligands with triphenylarsine has been well documented to assist slow transmetallations, 41 the softer and more labile arsine ligand facilitating the formation of the palladium-tin double-bond π-complex, which has been reported to be the rate-determining step in
Stille cross-couplings. 42 We were delighted to observe that performing the Stille coupling with tetramethyltin in the presence of triphenylarsine gave 19-methylgeldanamycin 6, albeit in moderate yield and with significant quantities of recovered geldanamycin (29% Having established a successful coupling protocol, we investigated the scope of the reaction with a range of stannane coupling partners, selected to introduce representative alkyl, alkenyl, aryl and hetaryl groups (Figure 2a ). Although a methyl group could be successfully incorporated at C-19, attempted coupling of other alkyl groups was unsuccessful. Likewise the reaction of iodogeldamycin 5 with allyl tri-n-butylstannane only gave a very poor yield (ca. 5%) of the 19-allyl compound. Both electron rich and electron deficient aromatic groups could also be coupled successfully in good to excellent yield. Heteroaromatic stannanes proved to be more variable under our conditions. Coupling of the 2-pyridyl group was problematic, with the product 12 isolated in a moderate yield of 30%.
However, furan and thiophene groups were successfully transferred, affording substrates 13 and 14 in excellent yields of 90% and 94% yield, respectively. The Stille products, following an aqueous work-up and purification (K 2 CO 3 /SiO 2 chromatography), 44 contained 10.5 ppm Pd, 7.9 ppm Sn and
As and undetectable levels of Cu as detected by inductively coupled plasma mass spectrometry (ICPMS) trace element analyses (for details, see Supplementary Information).
In the geldanamycin series of BQAs, it is the 17-allylamino (17-AAG) anddimethylaminoethylamino (17-DMAG) derivatives 2 and 3 that have shown the most clinical promise, and therefore we synthesized the corresponding AAG and DMAG analogues of our 19-substituted geldanamycin derivatives (Figure 2b ). This was readily achieved by heating the 17-methoxy compounds 6-14 with a 5-fold excess of allylamine or N.N-dimethylethylenediamine in THF, and gave the corresponding 17-amino derivatives in modest -excellent yield. is clear that the compact C-shaped conformation allows the hydrophobic surface area to be minimized by being 'buried' in the heart of the structure, whilst the hydrophilic moieties are exposed to the solvent. This observation would be consistent with the large difference in polarity observed by TLC analysis.
To confirm that 19-substitution caused a trans to cis amide change in conformation in the solid state, we sought evidence from X-ray crystallography. 19-(2-Furyl)geldanamycin 13 gave crystals (of its THF complex) that were suitable for X-ray diffraction. The molecule exhibited both the cisconfigured amide and also the 'C-clamp' conformation (see Supplementary Figure 12 ; CCDC reference 864025). Unsurprisingly, therefore, the conformation of macrocycle 13 is different to that of 19-unsubstituted geldanamycins that adopt a trans-amide conformation in the crystal; this is clearly seen by overlaying the structure of 13 and the published structure of compound 4 28 as depicted in Figure 3a . On the other hand, and in line with our original hypothesis, the isomerization from trans-to cis-amide induced by the 19-substituent does impart an overall 'C-clamp' conformation to the BQA macrocycle that is very similar to that of the protein-bound geldanamycin as shown in the overlaid structures in Figure 3b . 
Substitution at C-19 reduces toxicity in cells
A key tenet of our original hypothesis was that introduction of a substituent at C Culture conditions and the MTT assay are described in Supplementary Information.
Binding to Hsp90
We with Hsp90 (green and grey residues, respectively); e, geldanamycin 1 (green) and 19-methyl 17-DMAG 22 (gold) with Hsp90 (green and gold residues, respectively), and f, geldanamycin 1 (green) and 19-phenyl geldanamycin 8 (salmon) with Hsp90 (green and salmon residues, respectively). In general, in these geldanamycin analogues, the 19-substituents tend to alter binding to the protein through a positional change of the quinone group of the benzoquinone ansamycin. 
Inhibition of Hsp90 in cellular systems
X-ray crystallography clearly showed that 19-substituted derivatives do bind to the ATP-site in Hsp90. Therefore, we examined the ability of 19-substituted compounds to inhibit Hsp90 in cellular systems. A decrease in Hsp90 client proteins (including Raf1, Her2 and Cdc-2) and a compensatory increase in Hsp70 are the two most common biomarkers used for inhibition of Hsp90 in cells.
45-47
Initially we utilized MDA-468-NQ16 cells that over-express the quinone reductase NQO1, since we have shown that NQO1 potentiates Hsp90 inhibition due to the formation of the more active hydroquinone ansamycin, 45, 46 and worked with the 17-DMAG (alvespimycin) series.
In Figure 5a Results are representative of 3 separate experiments. β-Actin was used as a loading control.
In addition to their use as anticancer agents, Hsp90 inhibitors have attracted attention as potential protective agents against neurodegeneration due to their ability to induce a compensatory increase in other heat shock proteins that protect against aberrant protein folding and aggregation. [8] [9] [10] [11] [12] [13] [14] SH-SY5Y neuroblastoma cells are dopaminergic and have been used as a cellular model system of relevance to
Parkinson's disease. [48] [49] [50] In Figure 5c we demonstrate that both geldanamycin and 19-phenyl 
Methods
All experimental procedures, characterization data for all compounds and copies of the 1 H and 13 C NMR spectra, details of NMR studies, biological evaluations and protein crystallography are given in the Supplementary Information associated with this paper.
